// App-Quantinova.ai

THU0201 (2018) : A pooled analysis of three tnf-Α inhibitor biosimilar studies in patients with rheumatoid arthritis comparing radiographic progression by disease activity states

Researchers

Presenter

  • J.S. Smolen

Principal Investigators

  • M. Weinblatt

  • P. Emery

  • E. Keystone

  • M. Genovese

  • G. Myung

  • E. Hong

  • I. Baek

  • S. Lee

  • J. Ghil

Medical Centers

  • Medical University of Vienna, Vienna, Austria

  • Brigham & Women's Hospital, Boston, MA

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Mount Sinai Hospital, Toronto, ON, Canada

  • Stanford Univeresity Medical Center, Stanford, CA

  • Samsung Bioepis Co., Ltd., Incheon, Republic of Korea

Locations

  • Australia

  • United States

  • United Kingdom

  • Canada

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved